Related Experiment Video
Updated: Jul 9, 2026

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
Published on: July 18, 2012
Effects of the HDAC6/8 Inhibitor MC1568, Alone and in Combination With Fluconazole, in Non-Albicans Candida Species
Andrea Giammarino1, Chiara Lambona2, Alessia Raucci2
1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Abstract:
Fungal infections pose a severe health risk, particularly in immunocompromised individuals, with Candida species being a leading cause of bloodstream infections. The rise of non-albicans Candida (NAC) infections, accounting for 35%-65% of candidemia cases, underscores the urgent need for novel antifungal strategies. Current treatments, including echinocandins and azoles, are increasingly challenged by drug-resistant strains. This study evaluated the antifungal efficacy of three clinically approved histone deacetylase inhibitors (HDACi)-Vorinostat, Romidepsin, and Tucidinostat-along with the HDAC6/8-selective inhibitor MC1568, alone and in combination with Fluconazole. The Fluconazole/MC1568 combination exhibited significant synergistic effects, reducing biofilm formation and enhancing antifungal activity, particularly against C. guillermondii, C. lusitaniae, and C. tropicalis. In Galleria mellonella larvae, this combination increased survival by 70% in C. tropicalis infections. When tested in human retinal pigment epithelium (RPE) cells, three different MC1568/Fluconazole combinations displayed low toxicity. These findings highlight the potential of the HDAC6/8 inhibitor MC1568 as adjunct therapy to combat NAC infections, warranting further research to optimize antifungal efficacy while minimizing toxicity.
Insights
Novel antifungal therapies are crucial due to rising drug resistance in Candida infections. Combining Fluconazole with HDAC6/8 inhibitor MC1568 shows promise, reducing biofilms and enhancing efficacy against non-albicans Candida species.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Fungal infections, especially candidemia, are a significant health threat, particularly for immunocompromised patients.
- Non-albicans Candida (NAC) species increasingly cause infections, with rising resistance to existing antifungal drugs like azoles and echinocandins.
- There is an urgent need for new antifungal strategies to overcome drug resistance.
Purpose of the Study:
- To evaluate the antifungal efficacy of clinically approved histone deacetylase inhibitors (HDACi) and a selective HDAC6/8 inhibitor (MC1568).
- To assess the combination therapy of MC1568 with Fluconazole against NAC species.
- To determine the in vivo efficacy and in vitro toxicity of the MC1568/Fluconazole combination.
Main Methods:
- Screening of Vorinostat, Romidepsin, Tucidinostat, and MC1568 alone and with Fluconazole.
- Assessing biofilm formation and antifungal activity against NAC species.
- Evaluating efficacy in Galleria mellonella infection models and toxicity in human retinal pigment epithelium (RPE) cells.
Main Results:
- The combination of Fluconazole and MC1568 demonstrated significant synergistic antifungal effects.
- This combination effectively reduced biofilm formation and enhanced activity against Candida guillermondii, Candida lusitaniae, and Candida tropicalis.
- In vivo studies showed a 70% increase in survival rates against Candida tropicalis infections in Galleria mellonella larvae, with low toxicity observed in RPE cells.
Conclusions:
- The HDAC6/8 inhibitor MC1568, in combination with Fluconazole, shows significant potential as an adjunct therapy against NAC infections.
- This combination effectively combats biofilm formation and enhances antifungal activity.
- Further research is warranted to optimize this combination for clinical application against resistant fungal pathogens.
Related Concept Videos
Candidiasis
Antifungal Agents
Cryptococcal Meningitis

